Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis.
CONCLUSION: Early optimization of golimumab dose induces clinical response at week 14 in two thirds of UC patients and leads to long-term clinical benefit in over half of patients.
PMID: 30722703 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Colectomy | Corticosteroid Therapy | Inflammatory Bowel Disease | Research | Study | Ulcerative Colitis